TickerTalks
Browse all tickers →
TickerTalks›$SLS
SLSLS

SELLAS Life Sciences Group, Inc.

$SLS·$2.2B·Biotechnology·Healthcare
$13.24-0.7%YTD+165.4%1Y+629.0%
Mentions · last 7 days
2026-08-22: 53 posts687+8%
Price updated 3m ago·X counts updated 10d ago
SLSLS
$SLSSELLAS Life Sciences Group, Inc.
$13.24-0.75%687 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $SLS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-01

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Binary AML readout is the whole trade; Perceptive and OrbiMed reportedly bought puts, longs point to historical CR2 data.

SELLAS Life Sciences is a small-cap biotech whose entire equity narrative hinges on the imminent REGAL Phase 3 AML readout for its lead asset, GPS. The stock has 6x'd over twelve months on positioning into the event.

Why this is a pure binary rather than a compounder:

  • Revenue is effectively zero and losses are structural — last quarter revenue was zero, EPS negative $0.05, and consensus for the year is a $0.21 EPS loss on $36M revenue; nothing about the P&L supports the current $2.2B market cap outside the data.
  • The bull case has specific historical support — CR2 patients in prior GPS trials showed 21 months median overall survival versus 5.4 months in historical controls, and Vanguard's 9.3% stake increase adds institutional weight.
  • The bear case is equally specific — the BMF Reports short thesis argues GPS entered Phase 3 on a hand-picked 10-patient signal, and Perceptive and OrbiMed reportedly bought puts in Q2 — the smart-money hedge you'd see when institutions expect binary downside.
  • The tape reflects the mood — 82% of the 52-week range, 103% above the 200-day, volume slightly above average.
  • Cash runway is ~$138M as of June 30, so even a mixed readout keeps the equity alive; a clean miss is terminal.

REGAL is the whole trade: a primary-endpoint hit near CR2 prior data is a multi-bagger; a miss or a mixed signal validates the $1 target.

Agrees with X sentimentX is right that the setup is polarized — Vanguard's stake and the CR2 prior data are real bullish inputs, and Perceptive/OrbiMed put-buying plus the BMF short thesis are real bearish inputs; agree with the split framing, this is a genuine binary.

What to watch: The REGAL Phase 3 AML primary-endpoint readout — a hit near CR2 prior data is a multi-bagger, a miss or a mixed signal validates the $1 target; the Nov 11 earnings is only a cash-runway update, not the catalyst.

On the calendar: 2026-11-11 — Q3 earnings (REGAL readout expected sooner, undated)

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment74 posts analyzed · as of 2026-08-30

SELLAS is one of the most polarized threads in this batch, with the crowd split hard around the REGAL Phase 3 AML readout. Bulls cite Vanguard's 9.3% stake increase, Dr. Tsirigotis calling GPS the likely primary-endpoint winner, and prior CR2 data of 21 months median overall survival versus 5.4 in historical controls. A visible short camp, including a new BMF Reports piece, targets $1 post-data, arguing GPS entered Phase 3 on a hand-picked 10-patient signal. Perceptive, OrbiMed and others reportedly bought puts in Q2.

Read the AI verdict + X sentiment for $SLS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Developing galinpepimut-S cancer vaccine for acute myeloid leukemia and mesothelioma; late-stage immunotherapy biotech.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $SLS.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $SLS

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-48.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-29.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-47.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.05$-0.04-11.1%
Q1 2026May 12, 2026$-0.05$-0.06+16.7%
Q4 2025Mar 19, 2026$-0.05$-0.06+21.0%
Q3 2025Nov 12, 2025$-0.06$-0.06+5.3%
Next earningsWed, Nov 11·consensus EPS $-0.05

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.05$-8.8M
Q4 FY25$0———$-0.05$-4.9M
Q3 FY25$0———$-0.06$-7.1M
Q2 FY25$0———$-0.07$-7.3M

Forward consensus

5-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$36.1M$36.1M – $36.1M-$0.21-$0.21 – -$0.211
FY27$53.1M$53.1M – $53.1M-$0.13-$0.13 – -$0.131
FY28$122.0M$122.0M – $122.0M$0.01-$0.25 – $0.281
FY29$357.6M$357.6M – $357.6M$1.33$1.33 – $1.331
FY30$630.3M$630.3M – $630.3M$2.55$2.55 – $2.551

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.82%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+103.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 183.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.495-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 award) in window

See when $SLS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 258-K — Item 5.02: Officer or director change
AI summary

SELLAS Life Sciences updated and standardized executive severance arrangements for three senior officers on June 24, 2026, following a review with an independent compensation consultant. CEO Dr. Angelos Stergiou's employment agreement was amended, while CFO John Burns and Chief Development Officer Dr. Dragan Cicic received amended and restated severance and change-of-control agreements. No specific severance dollar amounts were disclosed in the filing body. Routine compensation governance — no operational or strategic change implied.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-33958 20-8099512 disclosed voting results from its annual or special meeting. rs. Annual Meeting of Stockholders On June 16, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in person or represented by proxy. At the Annual Meeting, the stockholders voted on the following five proposals and cast their vote...

S-3ASRAuto-shelf registrationMar 20S-3ASR
+ 17 other (4 13Gs · 3 earnings 8-Ks · 2 10-Qs · 2 routine 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surgesbenzinga.com·5d agoThis One Data Readout Could Make Or Break Sellas Life Sciences Groupseekingalpha.com·19d agoSELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·21d agoSELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalystseekingalpha.com·30d agoSELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Upseekingalpha.com·49d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$AMLX$ABCL$ABVX
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport